Alien Advantage: Pattern-Breaking Innovation/Manan Mehta, Rustam Esanov - Immigrants, Unshackled, mRNA+AI ~ Spark of Ages Ep 53

We explore how removing immigration friction and backing immigrant founders at day zero can produce outsized innovation, through the lens of a VC platform and a biotech founder reprogramming tumors with mRNA and AI. The conversation blends policy, venture economics, and a bold oncology thesis with practical advice and personal stories.

• immigrant advantage as resilience, clarity, and risk appetite
• Unshackled’s Day Zero model and economics
• technical visionaries and system disruptors archetypes
• turning tumors into immune allies with mRNA and AI
• off the shelf approach across solid tumors
• storytelling skills for technical CEOs
• curated community as capital and catalyst
• immigration policy takes on points systems and talent pipelines
• why fear based rules hurt innovation
• reflections on curiosity, kindness, and grit

What happens when you bet on a founder before there’s a product, revenue, or even a company? We bring together Manan Mehta, founding partner at Unshackled Ventures, and Rustam Esanov, co-founder and CEO of Reprogram Biosciences, to unpack how day‑zero investing meets deep tech ambition—and how that mix can upend cancer therapy.

Manan opens the curtain on Unshackled’s model: underwrite immigrant founders when capital and confidence are scarcest, handle immigration legal end‑to‑end, and curate a community that knows when to introduce the next believer. He breaks down their two founder archetypes—technical visionaries and system disruptors—plus the quotients that matter: intelligence, adversity, emotional, and social. We dig into why early belief earns better economics, how consensus‑driven VC misses mispriced opportunities, and what it takes to move a company from a first experiment to a milestone investors can’t ignore.

Rustam shares the personal spark behind his mission and the science powering it. Using AI‑guided design and mRNA, his team aims to reprogram tumor cells into immune‑like allies, opening the “fortress” from the inside so the body can attack solid tumors. He explains why an off‑the‑shelf approach beats personalization for scale, how early out‑of‑pocket experiments de‑risked the thesis, and the single most practical lesson he learned transitioning from bench science to CEO: tell a story so clear a teenager can understand it. 

Manan Mehta: https://www.linkedin.com/in/mananm/

Manan Mehta is the Founding Partner of Unshackled Ventures, the only inception-stage (pre-revenue, pre-product, pre-incorporation) venture fund focused entirely on backing immigrant-founded startups.  For over 11 years, Manan has led the firm, which provides capital, network access, and full immigration support, having sponsored over 300 immigration filings for founders, often before they incorporate their businesses.

Rustam Esanov:  https://www.linkedin.com/in/rustamesanov/

Rustam Esanov is the CEO and Co-founder of Reprogram Biosciences, a deep-tech company developing mRNA reprogramming therapeutics.  His mission is to turn tumors into immune-like allies to treat solid cancers by leveraging a proprietary AI platform to build a precision cell-reprogramming engine to solve one of the most complex challenges in medicine.

Website: https://www.position2.com/podcast/

Rajiv Parikh: https://www.linkedin.com/in/rajivparikh/

Sandeep Parikh: https://www.instagram.com/sandeepparikh/

Email us with any feedback for the show: sparkofages.podcast@position2.com